Zobrazeno 1 - 10
of 3 731
pro vyhledávání: ''
Autor:
Vieri Scotti, Beatrice Fantechi, Francesca Mazzoni, I. Stasi, Irene Pecora, Carmelo Tibaldi, Enrico Vasile, Chiara Caparello, Editta Baldini, Marianna Turrini, Lorenzo Antonuzzo, Francesca Federici, Andrea Camerini, Giulia Meoni, Daniele Pozzessere, Diana Giannarelli, Virginia Rossi, L.P. Ciccone
Publikováno v:
Anti-Cancer Agents in Medicinal Chemistry. 22:1278-1285
Background: In advanced non-small-cell lung cancer, without activating mutations and with PD-L1≥50%, Pembrolizumab monotherapy is the therapeutic standard in Europe. Objective: To evaluate retrospectively the safety and efficacy of this drug and to
Autor:
Samia Hajar Touimi, Noureddine Benjaafar, I Mbarki, Tayeb Kebdani, Patricia Agbanglanon, Norosoa Randriamarosona, Sanaa Elmajjaoui, Hanan Elkacemi
Publikováno v:
Bulletin du Cancer. 109:280-286
Summary Objective Radiotherapy remains an essential part of the management of locally advanced cervical cancer. Post-treatment surveillance allows for tumor response assessment and early detection of progressive prosecutions or local recurrences that
Autor:
Won Kyung Cho, Chel Hun Choi, Kyoung Won Noh, Byoung-Gie Kim, Bomi Kim, Yoo-Young Lee, Jeong-Won Lee, Won Soon Park, Duk-Soo Bae, Tae-Joong Kim
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Objective: This study aimed to evaluate the effect of waiting time from diagnosis to initiation of definitive concurrent chemoradiation (CCRT) on overall survival in patients with cervical cancer. Methods: Patients with cervical cancer who had defini
Autor:
Xiao Xiao, Wei-Xiong Xia, Shaomin Huang, Jingjing Miao, Fei Han, Lin Wang, Xiang Guo, Yan-Qun Xiang, Chong Zhao, Yinglin Peng, Boyu Chen, Xiaowu Deng, Huageng Huang, Xing Lv, Yingshan Liang, Manyi Zhu, Weiwei Xiao
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Purpose This study was aimed to investigate long-term survivals and toxicities of early-stage nasopharyngeal carcinoma (NPC) in endemic area, evaluating the role of chemotherapy in stage II patients.Materials and Methods Totally 187 patients with new
Autor:
Taro Shibuki, Toshihiko Mizuta, Mototsugu Shimokawa, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Masaru Fukahori, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Kenji Mitsugi, Kenta Nio, Yasushi Ide, Norio Ureshino, Tsuyoshi Shirakawa, Taiga Otsuka
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
BMC Cancer
BMC Cancer
Background No reliable nomogram has been developed until date for predicting the survival in patients with unresectable pancreatic cancer undergoing treatment with gemcitabine plus nab–paclitaxel (GnP) or FOLFIRINOX. Methods This analysis was condu
Autor:
Isabelle Ghelerter, Marie-Hélène Lafeuille, Mike Durkin, Joyce LaMori, Patrick Lefebvre, Lorie Ellis, Carmine Rossi, Dominic Pilon, Xuehua Ke
Publikováno v:
Future Oncology. 18:231-243
Aims: In light of the extended overall survival and improved quality of life provided by advanced prostate cancer (PC) oral therapies, this study aimed to describe treatment adherence to advanced PC oral therapies and evaluate associated patient char
Publikováno v:
Cancer Biomarkers. 32:559-567
BACKGROUND: CA125 level normalization at different chemotherapy cycles has been reported to be a prognosticator in advanced epithelial ovarian cancer. OBJECTIVE: In the present study, we investigated whether the time (in days) to CA125 normalization
Autor:
Li Pang, Zhiqiang Guo
Publikováno v:
Cancer Medicine, Vol 10, Iss 23, Pp 8558-8569 (2021)
Cancer Medicine
Cancer Medicine
Background There is currently no recognized first‐line treatment strategy for ovarian neuroendocrine tumors (NETs). Furthermore, because of the low incidence of ovarian NETs, no studies have reported prognostic statistics derived from large samples
Autor:
Jonn Wu, Cheryl Ho, Zamzam Al-Hashami, Bonnie Leung, S. Moore, Selina K. Wong, Alexandra Pender, Ying Wang, Aria Shokoohi
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 11, Iss 1, Pp 86-93 (2022)
Cancer Medicine, Vol 11, Iss 1, Pp 86-93 (2022)
The evolution of diagnosis and treatment of advanced nonsmall‐cell lung cancer (NSCLC) has led to increasing the use of targeted therapy and immune checkpoint inhibitors. The study goal was to assess the effect of molecular testing and the introduc
Publikováno v:
Leuk Lymphoma
Relapsed/refractory Primary Central Nervous System Lymphoma (R/R PCNSL) has a poor prognosis with no established preferred treatment. We report the efficacy and toxicity of a combination chemotherapy regimen: methotrexate, carmustine, etoposide, and